Abstracts

Viral Suppression and Retention 2-5 Years After ART Initiation in Pregnancy in Uganda

Recent studies have demonstrated that up to 40% of women are lost to follow-up after initiating antiretroviral therapy (ART) during pregnancy in Option B+ programs. Data are limited on long-term virologic outcomes and retention in care, particularly after cessation of breastfeeding. We evaluated retention in care and viral suppression (VS) 2-5 years postpartum among previously…

CCR5+CD8+ T-Cell Levels Are Associated With Cardiovascular Events in Patients on cART

Acute coronary syndrome (ACS) is one of the most frequent non-AIDS-defining Event (nADEs).  Previous cross-sectional studies have observed an increased incidence of atherosclerosis and higher T lymphocyte activation in HIV patients compared to healthy subjects. However, there are no longitudinal studies analyzing the characteristics of T and dendritic cells (DCs) phenotypes that precede an ischemic…

Soluble TWEAK May Predict Carotid Atherosclerosis in Treated HIV Infection

Despite potent antiretroviral therapy (ART), HIV-infected subjects remain at higher risk of cardiovascular disease (CVD) when compared to the general population.  Soluble Tumor Necrosis Factor Weak Inducer of Apopstosis (sTWEAK) is a cytokine that belongs to the tumor necrosis factor (TNF) family and has been proposed as a novel biomarker of cardiovascular disease risk, specifically…

Does Pulse-Wave Velocity Normalize With Increasing Time on ART? Evidence From CHER

Cross-sectional evidence strongly suggests increased prevalence of vascular disease in HIV+ children on antiretroviral therapy (ART) after adjusting for traditional atherosclerosis risk factors. Vascular abnormalities are typically associated with advanced HIV disease and with ART, particularly lopinavir/ritonavir (LPVr). Thus far, pediatric studies have focused on children initiating ART much later than 3 months of age.…

Changes in CVD Risk Factors With Early and Deferred ART in the START Trial

HIV infection and certain antiretroviral medications appear to contribute to cardiovascular disease (CVD) risk.  CVD events were similar between the early (at CD4 >500cells/µL) and deferred (to CD4 160mg/dL or use of lipid lowering drug), diabetes (diagnosis or fasting blood glucose ≥126 mg/dL) and hypertension (diagnosis or use of blood pressure medication) during follow-up were…

Cardiovascular Biomarkers After Switch to ABC/DTG/3TC: The STRIIVING Study

Improvements in inflammatory biomarker profiles have been documented in virologically-suppressed patients switching from PI and/or NNRTI to RAL and EVG. Because improvements in chronic inflammation may affect mortality and co-morbid disease development, we evaluated the effects of switch to ABC/DTG/3TC on markers of inflammation and immune activation. Participants were randomized 1:1 to switch to ABC/DTG/3TC…